Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 2Sarcoma 1Genitourinary 1Breast 1

Conditions

Sarcoma 2Mesothelioma 2Lung Neoplasms 2Esophageal Neoplasms 2Thymus Neoplasms 1Sarcoma, Ewing 1Neoplasms, Germ Cell and Embryonal 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Pemetrexed 8pembrolizumab 6Cisplatin 6LMB-100 3Carboplatin 3Radiosurgery 2Plicamycin 2Dexamethasone 2Cryotherapy 2vandetanib 1tremelimumab 1tocilizumab 1rebastinib 1pevonedistat 1perflutren 1nintedanib 1iodixanol 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1durvalumab 1defactinib 1anetumab ravtansine 1amatuximab 1alvocidib 1aldesleukin 1Vinorelbine 1Sulfur Hexafluoride 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Mesothelioma × Plicamycin × Clear all
NCT02859415 2022-04-05

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 10 charts
GastrointestinalGenitourinaryOther solid neoplasmSarcomaThoracic

Esophageal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Germ Cell and Embryonal, Sarcoma, Thymus Neoplasms, Colorectal Neoplasms

NCT01624090 2019-12-30

Mithramycin for Lung, Esophagus, and Other Chest Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
16 enrolled 13 charts
BreastGastrointestinalOther solid neoplasmThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡